足立康則,尾崎紀夫:SNRIの薬理学的プロファイルと作用機序-ミルナシプラン,デュロキセチン,venlafaxineの相違.SNRIのすべて第二版(小山 司,樋口輝彦 編),pp.57-62,先端医学社,東京,2010.表1より(表のデータ引用元:Koch,S.,Hemrick-Luecke, S.K, Thompson, L.K. et al. : Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology, 45 (7) : 935-944, 2003. 及び Vaishnavi, S.N., Nemeroff, C.B., Plott, S.J. et al. : Milnacipran : a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry, 55 (3) : 320-322,2004.)
Bosc, M. : Assessment of social functioning in depression. Compr. Psychiatry, 41 (1) :63-69, 2000.
Costa e Silva, J. : Randomized, double-blind comparison of venlafaxine and fluoxetine in out-patients with major depression. J. Clin. Psychiatry, 59 (7) : 352-357,1998.
Cunningham, L.A. : Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann. Clin. Psychiatry, 9 (3) : 157-164,1997.
Einarson, T.R., Arikian, S.R., Casciano, J. et al. : Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression : a meta-analysis of randomized controlled trials. Clin. Ther., 21 (2) : 296-308,1999.